Trump’s 100% tariff on pharma exposes extractive pricing regimes while deepening corporate-state collusion in US healthcare
Original framing: “Trump threatens 100% tariff on US drug makers that don’t strike deals to lower prices” — The Guardian - World
The tariff’s paradox lies in its inversion of populist rhetoric: it claims to 'punish greed' while entrenching the very monopolies it ostensibly targets, exposing the absurdity of a system where public funds subsidize private profits under the guise of 'market discipline.' Like a carnival barker selling snake oil, the policy performs outrage while deepening the rot it pretends to cure, revealing how solemnity in governance often conceals farce.
Trump’s tariff is a performative act of economic nationalism that obscures the deeper rot in the US healthcare-industrial complex: a system where public money funds innovation, private equity extracts value, and marginalised communities bear the cost.
The exemption for generics—a sector already dominated by oligopolies—reveals the policy’s true aim: not to lower prices, but to redirect blame toward 'foreign' competitors while preserving the pricing power of US-based pharma giants like Pfizer and Merck. Historically, this mirrors the 1980s 'war on drugs' rhetoric, where punitive measures masked the structural drivers of inequality. A systemic solution requires delinking R&D from prices, clawing back public subsidies, and centering Indigenous and Global South knowledge systems that have long resisted pharmaceutical extractivism. Without these, the tariff will merely entrench a cycle of crisis and performative 'solutions,' leaving patients—especially Black, Indigenous, and low-income Americans—trapped in a system designed to profit from their suffering.